Printer Friendly

SOMATIX APPOINTS BERNS EXECUTIVE VICE PRESIDENT OF R&D

 SOMATIX APPOINTS BERNS EXECUTIVE VICE PRESIDENT OF R&D
 ALAMEDA, Calif., Aug. 17 /PRNewswire/ -- Somatix Therapy Corp.


(NASDAQ: SOMA) today announced the appointment of Antonius Berns, Ph.D., to a new position as the company's executive vice president of research and development. Berns, 47, currently heads the Division of Molecular Genetics at The Netherlands Cancer Institute in Amsterdam and occupies a chair in the Experimental Molecular Genetics of Inherited Diseases at the University of Amsterdam. His research has focused on the generation of animal model systems to study inherited and acquired diseases, such as cancer. The company has agreed to allow Berns to continue certain of his existing research activities at The Netherlands Cancer Institute.
 Berns stated, "In my judgement, Somatix has recruited an excellent group of scientists, and I am looking forward to working with them in this exciting and promising area of biomedical research."
 According to David Carter, chief executive officer, "Anton Berns is an internationally recognized scientist for whom I have the utmost respect. He is enormously talented and brings to the company impeccable scientific credentials. Anton is a scientific leader in the area of tumorigenesis and is considered an outstanding molecular oncologist by the scientific community. I fully expect him to further enhance the quality of the research now underway at Somatix."
 Somatix Therapy Corp. is a leader in the field of gene therapy. The company is focused on the genetic modification of selected human cells to enable the production and delivery of therapeutic substances within the patient's body. Somatix believes that gene therapy, which requires gene transfer technology, will provide a safe and effective means of delivering many therapeutic substances. Somatix has gene therapy programs in cancer, neural diseases and blood disorders.
 -0- 8/17/92
 /CONTACT: Julie Wood of Somatix Therapy, 510-748-3082/
 (SOMA) CO: Somatix Therapy Corp. ST: California IN: MTC SU: PER


RM -- SF007 -- 0623 08/17/92 15:39 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1992
Words:318
Previous Article:U.S. BANK PLANS MAJOR EXPANSION IN PIERCE COUNTY WITH NINE NEW BRANCH OFFICES SLATED
Next Article:EARLY RETIREMENT WINDOWS OFFERED BY NEARLY 40 PERCENT OF LARGE COMPANIES IN PAST TWO YEARS
Topics:


Related Articles
SOMATIX NAMES EXECUTIVE VICE PRESIDENT OF COMMERCIAL DEVELOPMENT
SOMATIX RECEIVES EXCLUSIVE WORLDWIDE LICENSE ON CANCER GENE THERAPY PATENT APPLICATION
SOMATIX ANNOUNCES APPOINTMENT OF ONCOLOGIST
SOMATIX ANNOUNCES APPOINTMENT OF RESEARCH SURGEON
SOMATIX REPORTS FIRST QUARTER RESULTS
SOMATIX REPORTS SECOND QUARTER RESULTS
Cell Genesys and Somatix Agree to Merge
James G. McArthur, Ph.D. Joins Phylogix as Vice President Research and Preclinical Development.
ARCA Discovery, Inc. Names Dr. Ann Lenich Hards Executive Vice President Regulatory Affairs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters